Clinical Trial Search

Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change

Primary: Change From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score at Week 16 — -7.79; -15.08; -11.07 Units on a scale — p=<0.001

Primary: Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to Baseline — 0.86; 0.53 Log transformed ratio — p=0.24

Primary: Percentage of Participants With ppPASI 75 Response at Week 16 (Period 1) — 17.5; 26.6; 14.1 percentage of participants — p=0.5722

Primary: Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at Week 20 Compared With Baseline — 16.50; 15.85; 16.50; 7.65 PPPASI Score — p=< 0.0001

Primary: Change From Baseline in Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI) — -6.0; -6.1 score on a scale — p=0.944

Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants

Primary: 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 — 1; 4 Participants

Primary: Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at…

Primary: Number of Participants Who Achieve at Least 75% Improvement in Palmoplantar Psoriasis Activity Severity Index (PPPASI) After 3 Infusions. — 4 participants

Primary: Percentage of Participants Who Achieve a PPPASI-50 at Week 16 — 40.9; 78.3 Percentage of Partcipants — p=0.0003

Primary: Percentage of Patients Achieving a Palmar/Plantar PGA Score of 0 or 1 at Week 16. — 0.375 percentage of participants

Primary: The Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI) at Week 16 From Baseline — -33.6; -44.2; -48.3; -46.2 Percentage of change in PPP ASI…

Primary: Percentages of Participants With Palmoplantar Investigator Global Assessmnet (ppIGA) 0 or 1 Response After 16 Weeks of Treatment — 22; 33.3; 1.5 Percentages of…

Primary: Percentage of Participants With Palmoplantar (pp) Pustular Psoriasis Area and Severity Index 50 (PASI) (ppPASI50) at Week 16 — 31.6; 31.6; 23.8 Percentage of…

Primary: Change From Baseline in the Palmo-plantar Pustulosis Psoriasis Area and Severity Index (PPPASI) Score at the End of Treatment (EOT) (Week 24) or at the Last Assessment…

Primary: Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels — 15; 15; 15; 14 participants

Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…

Primary: Mean Change From Baseline Psoriasis Area and Severity Index (PASI) at Week-24 After Treatment With Guselkumab. — 61.8 percent change from baseline PASI

Primary: Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From…

Primary: Palmoplantar Physician Global Assessment (ppPGA) — 3.47; 2.24 score on a scale

Primary: Time to First Generalized Pustular Psoriasis (GPP) Flare — 37.3; NA; NA; NA weeks — p=0.002

Primary: The Number of Subjects Who Achieve a 50% Reduction in the Palmoplantar Psoriasis Severity Index at 12 Weeks. — 8; 12 participants

Primary: Percentage of Patients With Adverse Reactions, Defined as Drug-related Adverse Events (AE) — 57.1 percentage of participants

Primary: Modified NAPSI Score (Nail Psoriasis Severity Index) — 6.3; 6.0 units on a scale

Primary: Clinical Improvement in PRP Severity and Body Surface Area — 15.2 units on a scale — p=<0.001

Primary: Percentage of Participants Achieving Clinical Response on the Clinical Global Impression (CGI) Scale — 75.0; 75.0 percentage of participants

Primary: Number of Participants Treated With Anakinra Who Achieve 50% Disease Improvement by the End of Week 12, as Measured by Total Body Surface Area Involvement (TBSAI50) — 7…

Primary: Proportion of Participants Achieving Clinical Response at Week 16 — 7 Participants

Primary: Number of Patients With Treatment Success at Week 16 Using Non-responder Imputation (Full Analysis Set) — 10; 2; 9; 1 Participants